216 related articles for article (PubMed ID: 26927942)
41. The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Yang J; He J; Yu M; Li T; Luo L; Liu P
Medicine (Baltimore); 2016 Dec; 95(50):e5599. PubMed ID: 27977596
[TBL] [Abstract][Full Text] [Related]
42. Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.
Jin J; Teng C; Li T
Drug Des Devel Ther; 2018; 12():475-480. PubMed ID: 29563772
[TBL] [Abstract][Full Text] [Related]
43. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Cunningham D; Chau I; Stocken DD; Valle JW; Smith D; Steward W; Harper PG; Dunn J; Tudur-Smith C; West J; Falk S; Crellin A; Adab F; Thompson J; Leonard P; Ostrowski J; Eatock M; Scheithauer W; Herrmann R; Neoptolemos JP
J Clin Oncol; 2009 Nov; 27(33):5513-8. PubMed ID: 19858379
[TBL] [Abstract][Full Text] [Related]
44. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
[TBL] [Abstract][Full Text] [Related]
45. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
Wang X; Ni Q; Jin M; Li Z; Wu Y; Zhao Y; Feng F
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):404-7. PubMed ID: 12408777
[TBL] [Abstract][Full Text] [Related]
46. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Zheng T; Jin J; Zhou L; Zhang Y
Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
[TBL] [Abstract][Full Text] [Related]
47. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Qi WX; Tang LN; He AN; Shen Z; Yao Y
Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
[TBL] [Abstract][Full Text] [Related]
48. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
[TBL] [Abstract][Full Text] [Related]
49. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
[TBL] [Abstract][Full Text] [Related]
50. A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
Novello S; Besse B; Felip E; Barlesi F; Mazieres J; Zalcman G; von Pawel J; Reck M; Cappuzzo F; Ferry D; Carcereny E; Santoro A; Garcia-Ribas I; Scagliotti G; Soria JC
Ann Oncol; 2014 Nov; 25(11):2156-2162. PubMed ID: 25139550
[TBL] [Abstract][Full Text] [Related]
51. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Ozaka M; Matsumura Y; Ishii H; Omuro Y; Itoi T; Mouri H; Hanada K; Kimura Y; Maetani I; Okabe Y; Tani M; Ikeda T; Hijioka S; Watanabe R; Ohoka S; Hirose Y; Suyama M; Egawa N; Sofuni A; Ikari T; Nakajima T
Cancer Chemother Pharmacol; 2012 May; 69(5):1197-204. PubMed ID: 22249272
[TBL] [Abstract][Full Text] [Related]
52. Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Wang Y; Xu L; Meng X; Qin Z; Wang Y; Chen C; Wang Y; Zhou X; Zhang Q; Xia J; Song N
Cell Physiol Biochem; 2018; 50(1):1-14. PubMed ID: 30293075
[TBL] [Abstract][Full Text] [Related]
53. A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Bergmann L; Maute L; Heil G; Rüssel J; Weidmann E; Köberle D; Fuxius S; Weigang-Köhler K; Aulitzky WE; Wörmann B; Hartung G; Moritz B; Edler L; Burkholder I; Scheulen ME; Richly H
Eur J Cancer; 2015 Jan; 51(1):27-36. PubMed ID: 25459392
[TBL] [Abstract][Full Text] [Related]
54. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.
Chao Y; Wu CY; Wang JP; Lee RC; Lee WP; Li CP
Cancer Chemother Pharmacol; 2013 Sep; 72(3):637-42. PubMed ID: 23912692
[TBL] [Abstract][Full Text] [Related]
55. The efficacy and safety of gemcitabine-based combination therapy
Zhang Z; He S; Wang P; Zhou Y
J Gastrointest Oncol; 2022 Aug; 13(4):1967-1980. PubMed ID: 36092340
[TBL] [Abstract][Full Text] [Related]
56. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
Chen L; Zhang M; Luo S
Tumour Biol; 2014 Nov; 35(11):11551-8. PubMed ID: 25129442
[TBL] [Abstract][Full Text] [Related]
57. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
58. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Lee HS; Chung MJ; Park JY; Bang S; Park SW; Kim HG; Noh MH; Lee SH; Kim YT; Kim HJ; Kim CD; Lee DK; Cho KB; Cho CM; Moon JH; Kim DU; Kang DH; Cheon YK; Choi HS; Kim TH; Kim JK; Moon J; Shin HJ; Song SY;
Medicine (Baltimore); 2017 Jan; 96(1):e5702. PubMed ID: 28072706
[TBL] [Abstract][Full Text] [Related]
59. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Sun C; Ansari D; Andersson R; Wu DQ
World J Gastroenterol; 2012 Sep; 18(35):4944-58. PubMed ID: 23002368
[TBL] [Abstract][Full Text] [Related]
60. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
